Tryp Therapeutics | Company Profile
CSE: TRYP
Latest Sector Updates
Tryp Therapeutics is a pharmaceutical company focused on identifying the developing clinical-stage compounds for orphan diseases with high unmet clinical needs. Tryp’s psilocybin for neuropsychiatric disorders (PFN) is focused on developing synthetic psilocybin as a new class of drug for specific neuro-psychiatric based disorders, including fibromyalgia and eating disorders.
Tryp is also developing an oral formulation of razoxane for the treatment of soft tissue sarcoma, it believes this formulation (TRP-1001) should qualify for Orphan Drug status.
Stock information
Contact Information
Website: https://tryptherapeutics.com/
Contact Email:Investors@tryptherapeutics.com
Corporate Presentation Link: click here
Latest Tryp Therapeutics News
Tryp Therapeutics to Participate in Wonderland: Miami on November 8
San Diego, California–(Newsfile Corp. – November 4, 2021) – – Nov. 4, 2021 – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (” Tryp ” or the ” Company “), a ...
Tryp Therapeutics to Present at the KSCA Psychedelics Virtual Investor Conference
San Diego, California–(Newsfile Corp. – October 12, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (” Tryp ” or the ” Company “), a pharmaceutical company developing psilocybin-based compounds for diseases ...
Tryp Therapeutics Announces Collaboration with Researchers at the University of Wisconsin-Madison
San Diego, California–(Newsfile Corp. – October 7, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (” Tryp ” or the ” Company “), a pharmaceutical company focused on developing psilocybin-based compounds ...
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Training for Upcoming Phase 2a Psychedelics Trial Targeting Eating Disorders
Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions ...
Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida
San Diego, California–(Newsfile Corp. – August 24, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds ...
Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor
San Diego, California–(Newsfile Corp. – August 18, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds ...
